News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

University of Chicago Study Points to New Target for Cancers Resistant to Iressa and Herceptin


9/5/2012 7:32:00 AM

A more-sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors. The HER family of receptors has been linked to the development of a wide variety of human cancers. HER1 inhibitors such Iressa and HER2 inhibitors such as Herceptin are commonly used in the clinic for treatment of small cell lung carcinoma and breast cancer. A recent study suggests that HER3 levels can predict reduced breast cancer survival. However, HER3 inhibitors are not currently used in treatment.

Read at ScienceDaily
Read at News Release
Read at MedicalXpress
Read at Newswise
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES